BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

TRPM7, a divalent cation-selective channel with kinase domains, has been widely reported
to potentially affect cancers. In this study, we conducted multiple bioinformatic analyses …

BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins
which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the …

Insight into the critical role of B-cell receptor signaling for the pathogenesis of chronic
lymphocytic leukemia (CLL) led to the development of targeted therapies directed at key …

Although the BH3-mimetic venetoclax is highly cytotoxic for chronic lymphocytic leukemia
(CLL) cells, some patients with CLL fail to clear minimal residual disease (MRD). We …

Simple Summary The development of BCL-2 inhibitors as a pivotal approach in cancer
treatment lies in their ability to effectively trigger apoptosis in tumor cells. Venetoclax, a …

As patients continue to live longer with chronic lymphocytic leukemia, it has become evident
that there is an unmet treatment need for patients who have progressed on multiple lines of …

Bruton's tyrosine kinase (BTK) plays a key role in the B-cell receptor (BCR) signaling
pathway and confers anti-apoptotic and proliferative properties to malignant B-cells in …

The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the
therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable …

Mantle cell lymphoma (MCL), an aggressive, but incurable B-cell lymphoma, is genetically
characterized by the t (11; 14) translocation, resulting in the overexpression of Cyclin D1. In …